Kidney transplantation

Kidney transplantation offers patients with Hepatitis C virus infection a survival advantage over remaining on dialysis, but it does not erase the clinical burden of infection. Instead, transplantation relocates the central problem into a more demanding period in which liver disease, extrahepatic complications, antiviral treatment, immunosuppression, and graft safety must be evaluated together. The decisive question is therefore not simply whether transplantation can be performed, but whether the candidate’s HCV status and liver condition permit kidney-alone transplantation, require continued surveillance, or point toward simultaneous liver–kidney transplantation.

Transplantation as a Conditional Survival Benefit

Kidney transplantation has been shown to improve survival in HCV-infected patients compared with continued dialysis. That advantage exists despite the fact that HCV infection adversely affects survival in both dialysis and transplant populations. The excess risk reflects hepatic and nonhepatic complications, including progressive liver injury and immune-complex disease, so transplantation is framed as a benefit that depends on disciplined selection rather than as an uncomplicated escape from dialysis.

The wider medical context makes this selection necessary. HCV is treated as a systemic infection capable of affecting the liver while also inducing autoimmune, dermatological, and renal disease. In patients with chronic kidney disease, the transplant decision therefore belongs to a larger field of nephrology, dialysis, hepatology, and transplantation. HCV-associated mixed cryoglobulinemia can produce purpura, arthralgias, neuropathy, hypocomplementemia, and kidney disease; its renal manifestations include proteinuria, hematuria, reduced eGFR, nephritic syndrome, and nephrotic syndrome. These complications can matter to transplant eligibility even when liver enzyme abnormalities are slight.

Screening and Staging Before Listing

The pretransplant pathway begins with screening for anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing. A positive antibody result alone does not establish chronic active infection: chronic infection requires both anti-HCV antibodies and detectable HCV RNA, with molecular assays able to detect concentrations around 15 IU/ml. Candidates found to have active infection must undergo a more extensive assessment of both hepatic and extrahepatic disease.

Liver injury is particularly important because studies found advanced liver disease in approximately 10–25% of kidney transplant candidates with HCV infection when biopsy was performed during pretransplant evaluation. The assessment examines the stage and grade of hepatic injury and may consider biochemical or morphological noninvasive tests, including FibroScan-based elastometry. Such methods can reduce the need for some biopsies and permit annual follow-up of fibrosis in untreated patients, but they had not achieved the accuracy and reliability of liver biopsy for this transplant population. The KDIGO Workgroup therefore recommended percutaneous liver biopsy for all HCV-infected patients being considered for kidney transplantation.

The result of staging determines whether kidney-alone transplantation is appropriate. Candidates with established or decompensated cirrhosis should be referred to a liver transplant team for consideration of simultaneous liver–kidney transplantation. This distinction prevents the kidney graft from being offered in isolation to a patient whose hepatic disease may already require a different transplant strategy. It also turns the biopsy from a diagnostic formality into a gatekeeping procedure that determines the organ combination and the intensity of subsequent monitoring.

Antiviral Timing and the Waiting List

There is no universal consensus on treating an actively viremic candidate before transplantation, but the evidence and clinical logic favor focusing efforts to eradicate HCV before the graft is implanted. Sustained virological response before transplantation is associated with a low risk of relapse after immunosuppression, and anecdotal evidence suggests that viral clearance may reduce the later risk of posttransplant diabetes and immune-complex-mediated glomerular disease in the allograft. The evidence is less certain about whether pretransplant clearance slows progression of liver injury, but the potential benefits are clinically important.

The timing of treatment is also shaped by the hazards of posttransplant therapy. Interferon use after transplantation is associated with an increased risk of renal allograft rejection. For that reason, attempts to eradicate HCV should generally be concentrated in the pretransplant period rather than postponed until after kidney transplantation. Antiviral therapy itself is difficult for patients with end-stage renal disease: flu-like symptoms, fever, fatigue, headache, myalgia, arthralgia, anemia, neutropenia, depression, and anxiety can reduce quality of life, lead to dose reduction in 35–42% of treated patients, and result in discontinuation in about 30%.

Waiting-list management does not end once a patient has been accepted. In some regions, deceased-donor waiting times approach five to seven years, creating a long interval in which liver disease may progress and eligibility may change. Patients who were never tested before listing should undergo anti-HCV antibody testing by enzyme immunoassay, with nucleic acid confirmation in low-prevalence settings, or direct nucleic acid testing in high-prevalence settings. A patient with a positive nucleic acid test should be placed on hold and referred to a hepatologist for evaluation and possible treatment.

Patients who achieved sustained virological response before transplantation should undergo nucleic acid testing at least annually to confirm that the response remains durable. Relapse similarly warrants hold status and specialist referral for possible retreatment. Candidates who remain viremic require annual assessment of liver disease. In a small follow-up group, 8 of 13 patients, or 62%, showed worsening liver histology while still waiting for transplantation, compared with 7 of 31, or 23%, whose repeat biopsies were obtained after transplantation. The contrast underscores that waiting is not a neutral interval: without surveillance, the disease that initially permitted kidney-alone transplantation can evolve into a condition requiring a different strategy.

Clinical Burden Beyond the Liver

The transplant decision is influenced by the effects of HCV across the patient’s whole clinical life. In long-term dialysis, HCV-related liver disease is often asymptomatic, and symptoms such as fatigue, asthenia, and cognitive impairment may be difficult to distinguish from the ordinary burdens of dialysis. Biochemical clues can nonetheless appear. In a United States cohort of 13,664 patients receiving long-term dialysis, anti-HCV seropositivity was independently associated with serum alkaline phosphatase activity. HCV-infected patients also had higher intact parathormone levels, 422 ± 423 versus 338 ± 356 pg/ml, an observation linked to hepatic osteodystrophy. Cirrhosis remained relatively infrequent in Western dialysis registries, at approximately 1.5–2%, but its consequences are too serious to ignore during transplant assessment.

The infection’s history in dialysis also explains why transplant programs insist on testing and infection-control vigilance. Before HCV was identified as the principal cause of non-A, non-B hepatitis, transfusions were common in dialysis and carried substantial risk. The risk of posttransfusion hepatitis C fell from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million blood units, in the United States after blood screening improved. Attention consequently shifted toward nosocomial transmission within hemodialysis units, where prevalence correlated with time on dialysis, exceeded that observed in peritoneal dialysis or home hemodialysis, and remained substantial even among patients who had never been transfused.

HCV also bears on survival and lived experience while patients wait. HCV viremia was independently associated with increased aortic stiffness in a prospective study of 94 dialysis patients, including 17 who were HCV positive; the reported odds ratio for high pulse-wave velocity was 9.7. Other observational evidence did not show a statistically significant unadjusted association between HCV and cardiovascular mortality, illustrating the uncertainty and tension within the evidence base. Quality of life provides another dimension: among 165 regular dialysis patients, 83 of whom were anti-HCV positive, anti-HCV status was independently related to a lower mental component summary score on the SF-36, while no association was found with the physical component summary score. Depression, fatigue, cognitive impairment, and anxiety about long-term health may therefore make the waiting period clinically consequential even when liver disease remains silent.

Significance for Transplant Practice

Kidney transplantation in the setting of HCV is best understood as a coordinated sequence rather than a single operative act. Screening distinguishes prior exposure from active infection; biopsy establishes the severity of liver disease; specialist review identifies candidates who may need simultaneous liver–kidney transplantation; antiviral treatment is considered against its toxicity and the dangers of posttransplant interferon; and repeated testing protects the waiting list from silent relapse or progression.

The procedure’s significance lies in this institutional choreography. HCV-infected candidates are not excluded automatically, because transplantation can offer a survival advantage over dialysis. Nor are they treated as ordinary kidney-alone candidates, because immunosuppression may accelerate liver disease and because posttransplant interferon may threaten the renal allograft through rejection. The transplant pathway therefore converts virologic status, biopsy findings, waiting time, and treatment response into an ongoing eligibility judgment. Its central achievement is not merely replacing renal function, but aligning organ selection, infection control, liver prognosis, and long-term graft protection around the changing risks of HCV.